Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Thursday, December 1, 2011
Wednesday, September 14, 2011
Bold experimental treatment uses form of HIV to kill cancer
By Laura Shin | September 14, 2011, 5:41 AM PDT SMARTPLANET.COM
A bold experimental treatment has finally succeeded in accomplishing a goal that has eluded doctors for decades: it has trained the immune systems of cancer patients to search out and kill cancer cells.
The New York Timesreports, in a novel twist, that the doctors used a disabled form of HIV-1, the virus that causes AIDS, to deliver the new genes that would program the person’s own cells to attack the cancer.
The University of Pennsylvania doctors have tried the experimental treatment in three leukemia patients, two of whom went into full remission and one of whom has had a partial remission in which his leukemia remains in lessened form.
They published the results of their experiment with the first patient, William Ludwig, in the New England Journal of Medicine and Science Translational Medicine.
Results in first patient
The doctors — Dr. Carl June of the Abramson Cancer Center at the University of Pennsylvaniaand colleagues Dr. David L. Porter, Bruce Levine and Michael Kalos — began by removing a billion of Ludwig’s T-cells, which are white blood cells that fight tumors and viruses.
They then altered the genes of the T-cells so they would attack cancer, and returned those modified T-cells to his bloodstream.
For the first ten days, nothing happened. But then, according to the Times, “hell broke loose in his hospital room. He began shaking with chills. His temperature shot up. His blood pressure shot down. He became so ill that doctors moved him into intensive care and warned that he might die. His family gathered at the hospital, fearing the worst.”
But within a few weeks, the fevers subsided, leaving no trace of cancer in their wake. No leukemic cells were found in his blood or bone marrow, and doctors calculated that two pounds of cancer cells had been killed off.
A year later, Ludwig’s remission remains complete. He has gained 40 pounds, plays golf, does yard work and travels with his wife in an R.V. Before the study, he sometimes could barely get out of bed and frequently suffered bouts of pneumonia. “I have my life back,” he told the Times.
How the therapy works and uses the HIV virus
In order for T-cells to kill cancer cells, they must be able to do several things: recognize the cancer, fight it, multiply and continue living inside the patient. Previous attempts to make T-cells do all these things failed, resulting in cells that, for instance, could only temporarily fight tumors.
However, this experiment enabled the modified T-cells to multiply to 1,000 to 10,000 times the amount originally altered by the researchers. In those numbers, they wiped out the cancer and then gradually diminished, but there remains a population of memory cells that could proliferate if needed.
The particular type of leukemia treated in this case was chronic lymphocytic leukemia, which afflicts B-cells. The doctors gave the T-cells genes that would make them find and attack a protein found on all B-cells, whether they are healthy or leukemic.
But it is not easy to decide which genes to insert and how to insert them. Viruses are natural delivery vehicles because they specialize in invading the genes of cells. In this case, because doctors wanted to modify T-cells, the AIDS virus was chosen because it naturally invades T-cells.
While other researchers have used HIV-1 to insert DNA into cells in gene therapy for other diseases, Dr. June and his colleagues were the first to use it in gene therapy for cancer patients.
This particular form of HIV-1 was no longer dangerous because other researchers had added DNA from humans, mice and cows and from a virus that infects woodchucks and another that infects cows.
But this type of therapy is not without risks. In other experiments, engineered T-cells have attacked the healthy tissue of patients. And, having been done in only three patients, the new T-cell treatment is not yet proven to work and has not yet been mass-produced by the drug industry.
Dr. June said his team’s next focus is using T-cells to attack solid tumors, such as mesothelioma and ovarian and pancreatic cancer.
Watch them discussing their method in this video:
via: The New York Times
photo: the engineered T-cells with magnetic beads attached to them; the beads are removed prior to infusion into the patient. (University of Pennsylvania)
Saturday, July 23, 2011
PET/MRI creates diagnostic-quality images
© This article copyright 2010 by AuntMinnie.com. Any copying, republication or redistribution of AuntMinnie.com content is expressly prohibited without the prior written consent ofAuntMinnie.com.
Structural, functional and molecular imaging of patients with brain tumours is feasible with diagnostic imaging quality using simultaneous hybrid PET/MR image acquisition, according to a study in the August issue of the Journal of Nuclear Medicine.
A pilot study in Germany of 10 patients with intracranial masses found no significant artefacts or distortions using a hybrid scanner configuration that features an MRI-compatible PET insert placed in the magnet bore. The lead author of the study was Andreas Boss, from the department of diagnostic and interventional radiology at Eberhard Karls University Tübingen in Germany (JNM 51 1198).
As the authors noted, previous studies have indicated that only half of low-grade gliomas can be correctly classified using conventional contrast-enhanced MRI. In addition, conventional MRI may be insensitive to post-therapy changes. With PET's ability to provide biochemical and metabolic information, researchers surmised that the two modalities together "may increase diagnostic accuracy over the single modalities."
Between August 2008 and November 2009, 10 patients with a median age of 51 years (range, 34 to 73 years) participated in the pilot study. All patients initially received a brain PET/CT scan, followed immediately by PET/MRI.
Patient diagnoses
At the time of the patient referrals, diagnoses included three cases of meningioma, two patients with low-grade astrocytoma, two cases of glioblastoma, and one case each of suspected low-grade astrocytoma, anaplastic astrocytoma, and atypical neurocytoma.
For the glial tumours, the radiotracer carbon-11 (C-11) methionine was used for PET imaging. In the cases of meningiomas, gallium-68 DOTA-tyr3-octreotide (Ga-68 DOTATOC) was administered.
Data acquisition from the PET scanner (Hi-Rez Biograph 16, Siemens Healthcare, Erlangen, Germany) started at 30 minutes after the injection of methionine and lasted for eight minutes. When DOTATOC was used, acquisition started at 20 minutes after injection and lasted for four minutes. A noncontrast-enhanced low-dose CT scan was used for attenuation correction in the glioma patients, while a contrast-enhanced CT scan was used for meningioma patients.
PET/MRI exams
All PET/MRI scans were performed with a hybrid PET/MRI system capable of simultaneous PET/MR imaging of the brain and skull base. The system consisted of an MRI-compatible PET scanner (BrainPET, Siemens), which was inserted into a modified 3-tesla whole-body MRI scanner (Magnetom Trio Tim, Siemens).
![]() |
| PET/MR images |
The researchers acquired PET and MRI data simultaneously, starting 30 to 60 minutes after PET/CT acquisition. The PET scan was conducted for 30 minutes, producing approximately 5 GB of raw data. The PET datasets then were reconstructed by 3D algorithm. Attenuation maps were computed from 3D MRI datasets using an algorithm combining pattern recognition and atlas registration.
Upon review of the resulting images, the researchers determined that the MRI datasets acquired during simultaneous PET acquisition "showed diagnostic image quality, without apparent artefacts or distortions."
The one exception was when a 4 mm Gaussian filter was not used and the PET datasets from concurrent PET/MRI scans "exhibited slight streak artefacts, which were best visible in the sagittal and coronal reformations," the researchers noted. "After filtering, these artefacts were hardly visible."
![]() |
| PET/CT vs PET/MRI |
The group also found that radiotracer decay between the PET/CT and PET/MRI acquisitions was effectively compensated by the longer scanning duration and better scanner sensitivity.
"Our study indicates that hybrid PET/MRI of intracranial tumours using C-11 methionine or Ga-68 DOTATOC can be reliably performed," Boss and his colleagues wrote. "The image quality and quantitative data achieved using PET/MRI is similar to that using PET/CT."
In addition, the authors noted that the combination of PET with MRI, instead of CT, "offers many advantages, such as higher soft-tissue contrast; reduced radiation exposure; and advanced MRI techniques such as perfusion imaging, diffusion imaging, and MR spectroscopy."
Additional clinical benefits are that PET with MRI can reduce a patient's exposure to ionizing radiation, which is present with CT.
© This article copyright 2010 by AuntMinnie.com. Any copying, republication or redistribution of AuntMinnie.com content is expressly prohibited without the prior written consent ofAuntMinnie.com.
About the author
Wayne Forrest is an AuntMinnie.com staff writer.
Monday, May 30, 2011
Ibuprofen to be used in cancer treatment?
27th May 2011-www.spirehealthcare.com
The painkiller ibuprofen could become a part of cancer treatment after a study found that it stifles cancer growth.
A team of Cancer Research UK scientists based at the University of Bath found that a class of common painkillers, which includes ibuprofen, could interact with a protein which fuels cancer growth.Non steroidal anti-inflammatory drugs are all processed by the body through the protein AMACR, which is overactive in prostate, bowel and various others types of cancer.
Lead author Dr Matthew Lloyd, said: "Some early laboratory studies have suggested that high doses of ibuprofen can halt the growth of prostate cancer cells, but the reasons for this aren't well understood."
He added that understanding more about how this protein acts and what molecules it interacts with could provide vital clues about future treatments for prostate cancer.
According to figures from Cancer Research UK, prostate cancer affects over 37,000 men in the UK. Around a quarter of all new cases of cancer diagnosed in men are prostate cancers.
Posted by Jeanette Royston
1 - Woodman et al, Chiral inversion of 2-arylpropional-CoA esters by human alpha-methyylacyl-CoA racemase 1A (P504S) - a potential mechanism for the anti-cancer effects of ibuprofen (2011), Chemical Communications.
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.
Tuesday, March 22, 2011
Oncologists use robots to fight cancer
by: www.smartplanet.com
year, Jean Stuetzle, 92, learned she had lung cancer and was given few options to make her well again. Then, she visited radiation oncologist Robert Sinha at El Camino Hospital in Silicon Valley. He told Jean about CyberKnife, a non-invasive procedure that uses a robot and targeted radiation to eliminate cancerous tumors. SmartPlanet looks at the new technology and how it's working on cancer patients like Stuetzle.
year, Jean Stuetzle, 92, learned she had lung cancer and was given few options to make her well again. Then, she visited radiation oncologist Robert Sinha at El Camino Hospital in Silicon Valley. He told Jean about CyberKnife, a non-invasive procedure that uses a robot and targeted radiation to eliminate cancerous tumors. SmartPlanet looks at the new technology and how it's working on cancer patients like Stuetzle.
Tuesday, March 15, 2011
Surgery helps men regain fertility after cancer
WASHINGTON (AP) — New research shows a painstaking surgical technique can help some men deemed infertile because of childhood cancer treatment to become fathers after all.
Many of the cancer treatments that can save lives also leave survivors infertile. Young men can bank sperm if they're told in time, but many aren't. And experiments to find options for children diagnosed before puberty are only now beginning.
Researchers at New York-Presbyterian Hospital and Weill Cornell Medical Center pioneered an option a decade ago for men deemed sterile for a number of reasons.
Now they have long-term data showing the technique can work in some childhood cancer survivors whose only other options would have been adoption or using donor sperm.
Surgeons essentially perform tiny biopsies of testicular tissue to hunt any pockets of hidden sperm, which then are used in standard in vitro fertilization to attempt a partner's pregnancy.
In cancer survivors, they were able to extract small amounts of sperm from more than a third of the men — 27 of 73. Doctors then attempted injecting the sperm into a partner's eggs in hopes of pregnancy. The result: 20 children were born, including five pairs of twins, the researchers reported Monday in the Journal of Clinical Oncology.
Being able to find what are essentially stray sperm cells is dramatic but doesn't mean the technique will help everyone, cautions Dr. Peter Schlegel, urology chairman at NY-Presbyterian/Weill Cornell.
"Chances of successful treatment before were thought to be zero. So yes, we're far better than zero but certainly it's not absolute that if you go in for treatment, that you're going to be successful," he said.
The new study found that the best chance for sperm retrieval was among men who'd been treated for testicular cancer, while survivors of sarcoma had the lowest chance. That's because of varying treatments for different types of cancer.
Sperm is made in tiny tubes inside the testicles, which can be seen under an operating-room microscope, Schlegel explained. Flat tubes probably contain no sperm, while larger ones are removed to see if they do.
The surgery costs about $10,000 to $12,000, in addition to the costs of IVF, he said. It's already offered at various medical centers around the country.
"This study gives men a new way to achieve fertility and the potential of parenthood," Dr. Lisa Diller of the American Society of Clinical Oncology said in a statement.
Copyright © 2011 The Associated Press. All rights reserved.
by www.google.com/hostednews
Thursday, March 10, 2011
Intraoperative Radiation Therapy (IORT)
Intraoperative radiation therapy (IORT) is an intensive radiation treatment that delivers a concentrated beam of radiation to tumors as they are located during surgery. IORT allows direct radiation to the tumor while sparing normal surrounding tissue. The type of IORT most commonly used at Mayo Clinic is also called intraoperative electron radiation therapy, or IOERT.
Thousands of people have received IORT treatment at Mayo Clinic. The IORT team at Mayo Clinic includes specialists in radiation oncology who perform the procedure, surgery,anesthesiology and pathology. In Arizona, Mayo Clinic is one of only a few institutions in the United States that uses a Mobetron, a mobile device that can provide radiation therapy in the operating room.
Conditions treated with IORT
IORT is used for cancer that cannot be cured with surgery alone and for tumors that are either attached or close to vital tissues. Recurrent rectal cancer is the most common condition treated with IORT at Mayo Clinic. IORT is also used to treat:
- Cervical, uterine and ovarian cancers
- Prostate, bladder and kidney cancers
- Stomach, pancreatic, colon, rectal and anal cancers
- Soft tissue sarcoma
For people who have recurring cancer and people who have locally advanced cancers, IORT can be an effective therapy in achieving long-term tumor control.
How it works
IORT is almost always used along with external radiation prior to surgery. During surgery, after the surgeon removes as much of the tumor as possible, a machine called a linear accelerator delivers a concentrated beam of electron radiation directly to the tumors. The surgeon moves healthy organs out of the radiation field to prevent damage, and special tubes are used to focus the beams safely on the tumor(s).
IORT also may be used when the remaining tumor is too small to see.
Advantages of IORT
IORT allows doctors to administer high doses of radiation to tumors without exposing nearby healthy organs to radiation. A single dose of intraoperative radiation may have as much effect on the tumor as 10 to 20 daily radiation treatments. IORT offers the following benefits:
- Higher radiation dosage to cancer cells
- Faster radiation delivery during surgery
- Decreased radiation exposure to normal surrounding tissue
- Safer application compared with traditional radiation treatments
Like other treatments, IORT carries some risks. Mayo Clinic doctors discuss the benefits and risks with people to help them decide on a treatment.
by:www.mayoclinic.org
Sunday, March 6, 2011
NewGen radiation treatment effective in advanced head and neck cancer
Clinical trials at Helsinki University Central Hospital in Finland to assess the efficacy and safety of boron neutron capture therapy (BNCT) indicate that it has the potential to treat patients with advanced head and neck cancer who have not responded to previous treatments.
BNCT treatment produces radiation inside a tumor using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of phenylalanine, a special carrier substance. The tumor is then irradiated with low-energy neutrons.
Prof Heikki Joensuu and his team looked at 30 patients referred to HUCH's Department of Oncology from hospitals around Finland.
Apart from palliative chemotherapy, conventional treatment was no longer considered possible for the patients treated in the BNCT trial.
Seventy six percent of patients responded well to the treatment and 30 percent were still alive two years after treatment; although only one patient has survived 55 months.
"The positive results that we have achieved in treating head and neck tumours have convinced us of the benefits of further developing BNCT treatment and the services needed to administer it," said Boneca's Board of Directors chairman Seppo Pakkala.
"As BNCT saves healthy tissue, this promises to make it a good choice as a first-line therapy for patients with large head and neck tumours, avoiding the need for extensive surgery," he said.
"Additional studies will be needed, however, before BNCT can be adopted for this use. We would also like to extend the use of BNCT to treating tumours in other anatomical areas for which there are no forms of treatment currently available," he added.
The results of the study have recently been published in the International Journal of Radiation Oncology, Biology, Physics. (ANI) by: www.sify.com |
Labels:
BNCT,
cancer,
cancer treatment,
cervical cancer treatment
Monday, February 28, 2011
Dual-energy CT images cancer biomarkers
by : medicalphysicsweb
Spectral CT, an emerging technique that images using X-rays of more than one energy, can differentiate multiple tissue types or contrast agents within the body. At the SPIE Medical Imaging conference, held last week in Lake Buena Vista, FL, Cristian Badea from Duke University Medical Center (Durham, NC) described the application of dual-energy microCT to simultaneously image iodine and gold probes in vivo.
Spectral CT, an emerging technique that images using X-rays of more than one energy, can differentiate multiple tissue types or contrast agents within the body. At the SPIE Medical Imaging conference, held last week in Lake Buena Vista, FL, Cristian Badea from Duke University Medical Center (Durham, NC) described the application of dual-energy microCT to simultaneously image iodine and gold probes in vivo.
Badea and colleagues examined two nanoprobes: liposomal iodine (Lip-I) and gold nanoparticles. The Lip-I probes comprised an aqueous iohexol core surrounded by a lipid bilayer and PEGylated to ensure retention in the blood. The gold probe was AuroVist, a commercial contrast agent comprising 15 nm nanoparticles. Both probes are cleared from the body via the liver and spleen.
As gold and iodine exhibit different attenuation coefficient profiles, with K-edges at different energies (81 and 33 keV, respectively), it should be possible to distinguish the two by comparing X-ray images at different energies. To determine the optimal imaging parameters, Badea's team built a dual-energy microCT system, containing two X-ray tubes and two detectors.
First, the researchers used the Spektr computational tool to model the microCT system's performance, using a phantom containing varying volumes of the two probes and imaging at voltages from 40 to 150 kVp. Plots of contrast versus voltage revealed that at 40 kVp, signals from regions containing gold nanoparticles were brightest, while iodine provided maximum enhancement at around 70 and 80 kVp.
They then performed phantom experiments to measure CT enhancement for the probes across the same voltage range. The measured images agreed with the simulated results, showing maximum CT enhancement at 40 kVp for the gold nanoparticles and 80 kVp for the Lip-I. On a mass-concentration basis, the relative average enhancement of gold to iodine was 2.75 at 40 kVp and 1.58 at 80 kVp.
The team also used the phantom images to determine the limits of detectability of the two probes. Calculating the contrast-to-noise ratio at different concentrations revealed a limit of 20 mg/ml for the Lip-I probes and 10 mg/ml for gold nanoparticles. The use of averaging to reduce the noise improved these values to 15 and 6 mg/ml for Lip-I, and gold respectively.
In vivo assessment
The researchers also used the dual-energy microCT system to perform in vivo imaging of mice with colon cancer tumours. Mice were injected with 0.1 ml gold nanoparticles (with a gold concentration of 200 mg/ml) and then imaged 72 hours later at 40 and 80 kVp. The mice were then injected with 0.4 ml of the Lip-I probe and rescanned.
Maximum intensity projection images showed that Lip-I probes visualized the blood vessels, while gold probes revealed the liver, spleen and some enhancement into the tumour due to extravasation of the nanoparticles.
"This dual-energy microCT provides a way to image 3D vasculature and permeability in tumours," concluded Badea, associate professor of radiology at Duke's Center for In Vivo Microscopy. "These are both important biomarkers in cancer studies."
Labels:
cancer,
cancer biomarkers,
cancer treatment,
CT scan,
dual energy CT
Wednesday, February 23, 2011
Mammograms, now in 3D!
Hologic, Inc. just received approval from the Food and Drug Administration for the first ever 3-D digital mammography system for screening breast cancer.
Current mammograms – with 2-D X-ray breast pictures – are limited because tissues overlapping tissues could be hiding lesions or, on the other hand, make benign areas look suspect. (About 10% of women undergo additional testing for abnormalities that are later determined to be noncancerous.)
The Selenia Dimensions digital breast tomosynthesis system (pictured at right) reveals the inner architecture of the breast, free from the distortion typically caused by tissue shadowing or density, according to Hologic.
In studies where radiologists viewed 300 mammography exams, the 3-D system “could significantly enhance existing diagnosis and treatment approaches,”says FDA’s Jeffrey Shuren. The system had better accuracy and detection, visibility and sensitivity – a 7% improvement over 2-D.
The breast is briefly compressed during the exam, which combines 3-D and 2-D imaging – resulting in a stack of thin high-resolution image slices that provide a clear rendition of the structures within the breast and the surrounding tissue.
The combination of 2-D and 3-D images about doubled the radiation dose the patient received. However, the increase in cancer risk from having both a 2-D and 3-D exam is expected to be less than 1.5% compared to natural cancer incidence, and less than 1% compared to the risk from conventional 2-D imaging, according to the FDA.
Nearly 40 million mammograms are performed each year in the US. In 2009, there were 192,370 new cases of invasive breast cancer diagnosed, and over 40,000 American women died from it in that same year. If detected early, the 5-year survival rate is 98%, according to the American Cancer Society.
“We believe tomosynthesis has the potential to change how screening and diagnostic mammography is performed, and over time will prove invaluable to the earliest possible detection of breast cancer and in the reduction of unnecessary diagnostic interventions,” says Hologic president and CEO, Rob Cascella.
Dimensions 3-D, which is an add-on to Hologic’s 2-D system, has already been commercially available in more than 40 countries. The National Cancer Institute recommends women ages 40 and older have a mammogram every one to two years.
by: www.Smartplanet.com
Images: Hologic
Labels:
breast cancer,
cancer,
cancer treatment,
diagnostic radiology,
mammogram
Subscribe to:
Posts (Atom)






